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Heart failure, the clinical syndrome that
arises from inadequate cardiac pump
function, is known to be influenced by
genetic factors. However, thus far unbi-
ased genetic approaches in humans have
met with limited success in identifying
heart failure modifier genes [1], likely
because of substantial genetic heterogene-
ity between patients and difficulty control-
ling environmental factors. These limita-
tions can be overcome in model systems
such as the mouse, where a wealth of
inbred lines, polymorphic markers, and
well-characterized heart failure models are
available. Taking advantage of these
resources, Wheeler and colleagues provide
in this issue of PLoS Genetics compelling
evidence that a little-studied, cardiac-
specific protein kinase, cardiac Troponin I-
interacting kinase (Tnni3k), is a strong mod-
ifier of the development of heart failure
[2].
Previously, this team reported strain
background–dependent differences in
heart failure endpoints, including left
ventricular contraction and survival, for
the calsequestrin (Casq1 or CSQ) transgenic
model of dilated cardiomyopathy [3,4].
Heart failure and death were accelerated
when the CSQ transgene was crossed into
the inbred C57BL6/J (B6) compared to
the DBA/2J (DBA) strain background.
The dominant B6 modifier locus, named
Hrtfm2, was mapped to chromosome 3.
Crosses between DBA/2J CSQ transgenic
and AKR/J (AKR) mice identified a
similar disease-accelerating locus mapping
to the same chromosomal region, and
haplotype analysis narrowed the candidate
interval to 2 Mb, encompassing seven
known genes [5]. In the present study,
Wheeler et al. [2] demonstrate that
cardiac expression of one of these genes,
Tnni3k, is 12-fold higher in B6 and AKR
than in DBA, and no significant differenc-
es were found in the other six genes. At the
protein level, TNNI3K is robustly ex-
pressed in B6 and AKR hearts, but not
detected in DBA hearts. This difference in
expression is likely due to an intronic SNP
in DBA that causes aberrant RNA splicing
and production of a frameshifted tran-
script, which in turn is degraded by
nonsense-mediated decay. Two lines of
evidence indicate that Tnni3k is the gene
underlying the Hrtfm2 locus. First, while
transgenic expression of Tnni3k in a largely
DBA background did not affect heart
function or survival in control mice, it
markedly accelerated heart failure in CSQ
transgenic mice. Second, congenic mice
containing the AKR Hrtfm2 region isolat-
ed in a DBA background exhibited both
increased Tnni3k expression and acceler-
ated death of CSQ transgenics.
Discovery of Tnni3k as a modifier of
murine heart failure identifies it as a
candidate for development of drugs to
treat heart failure. Its promise as a
pharmaceutical target is enhanced by
virtue of its cardiac-restricted expression
and by the potential ‘‘drugability’’ of
kinases. However, pursuit of Tnni3k as a
therapeutic target will require better
understanding of its endogenous function
and additional data linking of Tnni3k to
heart disease in humans. Tnni3k encodes a
cardiac-restricted kinase that belongs to
the MAPKKK family, with homology to
integrin-linked kinase (Ilk), Raf1, and Tak1
(MGI: Map3k7) [6]. The similar domain
structure of TNNI3K and ILK and the
interaction of TNNI3K with cardiac
troponin I (TNNI3) has suggested that
TNNI3K connects integrin signaling with
the sarcomere [6]. TNNI3K localized to
both the cytoplasm and the nucleus [6],
raising the possibility that TNNI3K en-
gages in nuclear-cytoplasmic shuttling,
coupling signals transduced in the sarco-
mere with transcriptional responses. Inter-
estingly, DBA mice that do not express
detectable TNNI3K protein are overtly
normal. Presumably, TNNI3K structure
and cardiac-restricted expression pattern
have been preserved through evolution
because they provide a selective advan-
tage. As with the renin-angiotensin and b-
adrenergic systems, inhibition of which are
mainstays of current heart failure therapy,
Tnni3k may participate in adaptive stress
responses that become deleterious in
pathological conditions such as heart
disease.
While the work of Wheeler et al. [2]
clearly links Tnni3k with accelerated dis-
ease progression in the CSQ heart failure
model, a crucial question is whether this
finding can be extrapolated to human
disease. Significant additional work will be
required to formally demonstrate that
Tnni3k activity modulates progression of
human heart disease, but two sets of data
suggest that the results may be relevant.
First, CSQ mice model many aspects of
human dilated cardiomyopathy. Overex-
pression of CSQ, the major calcium-
binding protein of the sarcoplasmic retic-
ulum, disrupts cardiomyocyte calcium
handling by reducing Ca
2+-induced Ca
2+
release and altering expression of Ca
2+-
uptake and -release proteins [7]. Calcium
is a central regulator of cardiomyocyte
growth and function, and CSQ mice
develop some calcium-handling abnormal-
ities that are a common feature of diseased
cardiomyocytes [8]. Second, Wheeler et
al. [2] examined the effect of elevated
Tnni3k expression in an independent
disease model, in which heart failure was
induced by constricting the transverse
aorta. Tnni3k exacerbated cardiac dysfunc-
tion in this pressure-overload model,
thereby providing important evidence that
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disease in a model that may be physiolog-
ically more directly relevant to human
heart disease.
As exemplified by the study of Wheeler
et al. [2], exploration of genetic variation
in mice can yield novel insights into
human disease mechanisms. At present
this resource has been underutilized,
despite the fact that it directly comple-
ments analysis of genetic variation in
human populations. Hopefully, improved
mapping tools, increasing availability of
strain-specific phenotyping data (e.g.,
http://www.jax.org/phenome [9]), and
successful studies such as that of Wheeler
et al. [2] will lead to more widespread use
of forward genetic approaches in mice to
inform translational research.
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